Poxel Expands Metabolic Pipeline Through Strategic Acquisition Agreement With DeuteRx For DRX-065, A Novel Clinical Stage Drug Candidate For NASH, And Other Programs

Press/Media

Period	30 Aug 2018

Media coverage

Title	Poxel Expands Metabolic Pipeline Through Strategic Acquisition Agreement With DeuteRx For DRX-065, A Novel Clinical Stage Drug Candidate For NASH, And Other Programs
Media name/outlet	Drug Discovery Online
Country/Territory	United States
Date	30/08/18
URL	https://www.drugdiscoveryonline.com/doc/poxel-expands-metabolic-acquisition-deuterx-clinical-stage-drug-nash-other-programs-0001
Persons	Scott Friedman